Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Cisplatin|DRUG: Nab-paclitaxel|DRUG: Pembrolizumab|DRUG: Olaparib
Sponsor: Fudan University
Collaborators: Merck Sharp & Dohme LLC